Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 13/20 | 0.54 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | EP300 | Q09472 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110287 | 0.82 | P2RX7 (0.46) | EP300ABCB1HPGDABCG2 | |
| SCHEMBL6223413 | 0.80 | FFAR1 (0.72) | FFAR1FFAR4TSPODRD3 | |
| SCHEMBL5779417 | 0.79 | SETDB1 (0.42) | FFAR1FFAR4ABCB1HPGDABCG2 | |
| SCHEMBL22953827 | 0.78 | TAAR1 (0.51) | FFAR1FFAR4EP300 | |
| SCHEMBL19212130 | 0.77 | AKR1B1 (0.44) | FFAR1FFAR4 | |
| SCHEMBL2553567 | 0.77 | PDPK1 (0.50) | — | |
| SCHEMBL29810587 | 0.76 | FFAR1 (0.53) | FFAR1FFAR4TSPODRD3 | |
| SCHEMBL5315954 | 0.76 | FFAR1 (0.53) | FFAR1FFAR4TSPODRD3 | |
| SCHEMBL19133477 | 0.76 | KAT2B (0.44) | FFAR1FFAR4 | |
| SCHEMBL19133478 | 0.76 | MEN1 (0.48) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | FFAR1 224/4885FFAR4 262/4885TSPO 2436/4885 |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | FFAR1 390/4885FFAR4 622/4885TSPO 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.